STOCK TITAN

Emergent BioSolutions (NYSE: EBS) chair granted RSUs and stock options as board pay

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Emergent BioSolutions Inc. director and Chairman Zsolt Harsanyi received equity compensation in the form of restricted stock units and stock options. He was granted 25,344 RSUs, each representing one share of common stock upon vesting, and 11,296 stock options with an exercise price of $7.99 per share. Both the RSUs and options vest on the day before the one-year anniversary of the grant date, contingent on his continued service on the board. Following these awards, Harsanyi directly holds 149,076 shares of Emergent BioSolutions common stock.

Positive

  • None.

Negative

  • None.
Insider Harsanyi Zsolt
Role Chairman
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 11,296 $0.00 --
Grant/Award Common Stock 25,344 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 11,296 shares (Direct, null); Common Stock — 149,076 shares (Direct, null)
Footnotes (1)
  1. Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
RSUs granted 25,344 units Annual non-employee director grant on April 30, 2026
Stock options granted 11,296 options Annual director option grant on April 30, 2026
Option exercise price $7.99 per share Exercise price for 11,296 stock options
Shares owned after grant 149,076 shares Common stock directly held after RSU award
Underlying shares for options 11,296 shares Common shares underlying new stock options
restricted stock units ("RSUs") financial
"Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Incentive Plan financial
"granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service"
A stock incentive plan is a company program that gives employees or directors pieces of ownership or the right to buy shares over time, similar to receiving a bonus paid in company stock instead of cash. Investors pay attention because these plans align staff incentives with long‑term company performance but can also dilute existing shareholders and affect reported profits when grants are expensed, so they influence both ownership percentages and financial results.
Black-Scholes value financial
"dividing by the Black-Scholes value of a single option calculated as of the date of the grant"
Annual Grant Vesting Date financial
"will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date")"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Harsanyi Zsolt

(Last)(First)(Middle)
300 PROFESSIONAL DR

(Street)
GAITHERSBURG MARYLAND 20879

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/30/2026A25,344(1)A$0149,076D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$7.9904/30/2026A11,296 (2)04/30/2033Common Stock11,296(3)$011,296D
Explanation of Responses:
1. Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
2. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
3. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Remarks:
/s/ Richard S. Lindahl, Attorney-in-fact05/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Emergent BioSolutions (EBS) director Zsolt Harsanyi receive in this Form 4?

Zsolt Harsanyi received equity compensation consisting of 25,344 restricted stock units and 11,296 stock options. These awards reflect standard non-employee director compensation under Emergent BioSolutions’ stock incentive plan for board and committee service.

What are the vesting terms of the new RSUs reported for EBS director Harsanyi?

The 25,344 RSUs vest on the day prior to the one-year anniversary of the grant date. Vesting requires Harsanyi to remain a member of Emergent BioSolutions’ board of directors through that Annual Grant Vesting Date.

What are the key terms of the stock options granted to EBS director Harsanyi?

Harsanyi received 11,296 stock options, each allowing purchase of one EBS common share at an exercise price of $7.99. These options vest on the same Annual Grant Vesting Date, subject to his continued board service through that date.

How many Emergent BioSolutions shares does Harsanyi hold after these grants?

After the RSU grant, Zsolt Harsanyi directly holds 149,076 shares of Emergent BioSolutions common stock. This figure reflects his direct ownership position reported immediately following the acquisition of the new restricted stock units.

How was the number of stock options for EBS director Harsanyi determined?

The option grant size was set by taking 25% of total non-employee director compensation value and dividing that amount by the Black-Scholes value of a single option calculated on the grant date, as disclosed in the footnotes.